Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Studies toward bivalent κ opioids derived from salvinorin A: heteromethylation of the furan ring reduces affinity.

Munro TA, Xu W, Ho DM, Liu-Chen LY, Cohen BM.

Beilstein J Org Chem. 2013 Dec 20;9:2916-24. doi: 10.3762/bjoc.9.328. eCollection 2013 Dec 20.

2.

Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.

Munro TA, Huang XP, Inglese C, Perrone MG, Van't Veer A, Carroll FI, Béguin C, Carlezon WA Jr, Colabufo NA, Cohen BM, Roth BL.

PLoS One. 2013 Aug 14;8(8):e70701. doi: 10.1371/journal.pone.0070701. eCollection 2013.

3.

Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM.

J Biol Chem. 2013 Aug 2;288(31):22387-98. doi: 10.1074/jbc.M113.476234. Epub 2013 Jun 17.

4.

Salvinorin B meth-oxy-methyl ether.

Munro TA, Ho DM, Cohen BM.

Acta Crystallogr Sect E Struct Rep Online. 2012 Nov 1;68(Pt 11):o3225-6. doi: 10.1107/S1600536812043449. Epub 2012 Oct 27.

5.

Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.

Munro TA, Berry LM, Van't Veer A, Béguin C, Carroll FI, Zhao Z, Carlezon WA Jr, Cohen BM.

BMC Pharmacol. 2012 May 29;12:5. doi: 10.1186/1471-2210-12-5.

6.

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.

Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM.

Psychopharmacology (Berl). 2011 Apr;214(4):933-9. doi: 10.1007/s00213-010-2103-5. Epub 2010 Dec 8.

7.

Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Hooker JM, Munro TA, Béguin C, Alexoff D, Shea C, Xu Y, Cohen BM.

Neuropharmacology. 2009 Sep;57(4):386-91. doi: 10.1016/j.neuropharm.2009.06.044. Epub 2009 Jul 8.

8.

Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Béguin C, Duncan KK, Munro TA, Ho DM, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

Bioorg Med Chem. 2009 Feb 1;17(3):1370-80. doi: 10.1016/j.bmc.2008.12.012. Epub 2008 Dec 14.

9.

Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA Jr, Cohen BM, Béguin C.

Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. Epub 2007 Oct 24.

10.

N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.

Béguin C, Potter DN, Dinieri JA, Munro TA, Richards MR, Paine TA, Berry L, Zhao Z, Roth BL, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

J Pharmacol Exp Ther. 2008 Jan;324(1):188-95. Epub 2007 Oct 19.

PMID:
17951511
11.

Confirmation of the NMR assignments of salvinorin A.

Munro TA.

Magn Reson Chem. 2007 Sep;45(9):801. No abstract available.

PMID:
17638315
12.

8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptor.

Munro TA, Duncan KK, Staples RJ, Xu W, Liu-Chen LY, Béguin C, Carlezon WA Jr, Cohen BM.

Beilstein J Org Chem. 2007 Jan 9;3:1.

13.

Autoxidation of salvinorin A under basic conditions.

Munro TA, Goetchius GW, Roth BL, Vortherms TA, Rizzacasa MA.

J Org Chem. 2005 Nov 25;70(24):10057-61.

14.

Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F.

J Med Chem. 2005 Jan 27;48(2):345-8.

15.

Divinatorins A-C, new neoclerodane diterpenoids from the controlled sage Salvia divinorum.

Bigham AK, Munro TA, Rizzacasa MA, Robins-Browne RM.

J Nat Prod. 2003 Sep;66(9):1242-4.

PMID:
14510607

Supplemental Content

Loading ...
Support Center